Holen Sie sich die Stockscreener-App
0.3677
0.99%
0.0036
Handel nachbörslich:
.37
0.0023
+0.63%
Schlusskurs vom Vortag:
$0.3641
Offen:
$0.37
24-Stunden-Volumen:
346.62K
Relative Volume:
0.60
Marktkapitalisierung:
$21.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-123.46M
KGV:
-0.142
EPS:
-2.59
Netto-Cashflow:
$-104.11M
1W Leistung:
+4.25%
1M Leistung:
-6.65%
6M Leistung:
-20.86%
1J Leistung:
-80.44%
1-Tages-Spanne:
$0.3566
$0.3781
1-Wochen-Bereich:
$0.34
$0.397
52-Wochen-Spanne:
$0.2601
$2.525
Bioatla Inc Stock (BCAB) Company Profile
Firmenname
Bioatla Inc
Sektor
Branche
Telefon
858-558-0708
Adresse
11085 TORREYANA ROAD, SAN DIEGO
Vergleichen Sie BCAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.3677 | 21.38M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-05-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | BTIG Research | Buy |
| 2021-01-11 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-01-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Bioatla Inc Aktie (BCAB) Neueste Nachrichten
BioAtla’s Earnings Call: Positive Clinical Progress Amid Financial Challenges - MSN
Is BioAtla Inc. stock bottoming outQuarterly Profit Summary & Fast Momentum Entry Tips - Newser
Using data filters to optimize entry into BioAtla Inc.2025 EndofYear Setup & High Conviction Trade Alerts - Newser
Has BioAtla Inc. formed a bullish divergenceTrade Entry Summary & Free Daily Entry Point Trade Alerts - Newser
How to forecast BioAtla Inc. trends using time seriesWeekly Loss Report & Weekly Hot Stock Watchlists - Newser
Combining price and volume data for BioAtla Inc.Stop Loss & High Accuracy Swing Entry Alerts - Newser
What technical models suggest about BioAtla Inc.’s comebackJuly 2025 Rallies & Verified Entry Point Detection - Newser
Will BioAtla Inc. see short term momentum2025 EndofYear Setup & Trade Opportunity Analysis - Newser
Exit strategy if you’re trapped in BioAtla Inc.Quarterly Trade Summary & Risk Managed Investment Signals - Newser
Can BioAtla Inc. rally from current levels2025 Support & Resistance & Capital Protection Trading Alerts - Newser
BioAtla downgraded to Market Perform from Outperform at Citizens JMP - MSN
JMP Securities Reiterates “Market Perform” Rating for BioAtla (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Rating Lowered to Market Perform at Citizens Jmp - Defense World
How sentiment analysis helps forecast BioAtla Inc.Weekly Trend Summary & AI Powered Market Trend Analysis - Newser
BioAtla's BCAB Downgraded to Market Perform by JMP Securities - AInvest
HC Wainwright Predicts BioAtla’s Q3 Earnings (NASDAQ:BCAB) - Defense World
BioAtla’s SWOT analysis: oncology biotech’s stock faces cash crunch - Investing.com
BioAtla stock downgraded by Citizens JMP on cash concerns - Investing.com Canada
Will BioAtla Inc. see short term momentum [2025 Market Trends]Accurate Intraday Trading Signals - Newser
Why BioAtla Inc. stock attracts strong analyst attentionDay Trading Plan with Entry Risk Management - Newser
Analysts Apply Wyckoff Model to BioAtla Inc. StockBuy Low Sell High Stock Watch Strategy in Focus - 선데이타임즈
BioAtla, Inc. (NASDAQ:BCAB) Q2 2025 Earnings Call Transcript - Insider Monkey
What makes BioAtla Inc. stock price move sharplyWatchlist Generator for Smart Money Signals - Newser
BioAtla Inc. stock trend outlook and recovery pathFree Stable Entry High Return Opportunities - Newser
Buy Signal for BioAtla Inc. Stock Key Technical Indicators to WatchFree Conservative Entry for High Return Setup - Newser
What institutional flow reveals about BioAtla Inc.Automated AI Forecast with Trading Alerts - Newser
BioAtla Inc. Testing Reversal Zone on Weekly ChartAI Trading Suggestions With Accuracy Focus Released - beatles.ru
Can BioAtla Inc. Outperform Peers After Recent PullbackFundamental + Technical Hybrid Stock Tips Shared - beatles.ru
Does BioAtla Inc. stock have upside surprise potentialDaily Breakout Recap Watch - sisaissue.com
BioAtla, Inc. Reports Q2 2025 Financial Results and Clinical Progress - TipRanks
Head-To-Head Review: Alzamend Neuro (NASDAQ:ALZN) & BioAtla (NASDAQ:BCAB) - Defense World
Sector ETF performance correlation with BioAtla Inc.Free Alpha Driven Watchlist With Alerts - Newser
Comparing BioAtla Inc. in custom built stock radarsFree Swing Setup With Technical Confirmation - Newser
BioAtla's Strategic Position in Immuno-Oncology and Partnership-Driven Growth - AInvest
BioAtla August 2025 slides: promising clinical data amid financial headwinds By Investing.com - Investing.com Nigeria
Earnings call transcript: Bioatla Q2 2025 misses EPS forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: Bioatla Q2 2025 misses EPS forecasts - Investing.com India
Finanzdaten der Bioatla Inc-Aktie (BCAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):